---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-031718"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:25:28.944685+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Calidi Biotherapeutics reports Q2 2024 net loss of $5.8M; cash at $1.0M; launches Nova Cell subsidiary

## Summary
- Net loss of $5.8M ($1.40 per share) vs. $12.5M loss ($14.24 per share) in Q2 2023.
- Cash and restricted cash total ~$1.0M as of June 30, 2024, down from $2.1M at Dec 31, 2023.
- Launched Nova Cell subsidiary with $2M investment from Dr. Ronald Rigor; received additional $1M into Calidi.
- Appointed Dr. George Peoples to Board of Directors and Dr. Mark Gilbert to Medical Advisory Board.
- Received new U.S. patent for SuperNova technology; raised $2.5M from warrant exercises in July/August 2024.

## SEC filing metadata
- accession: 0001493152-24-031718
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315224031718/0001493152-24-031718-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315224031718/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-031718
- JSON: https://secwatch.observer/filing/0001493152-24-031718.json
- Plain text: https://secwatch.observer/filing/0001493152-24-031718.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.